期刊文献+

~rognostic value of baseline C-reactive protein levels in patients mdergoing coronary revascularization 被引量:4

~rognostic value of baseline C-reactive protein levels in patients mdergoing coronary revascularization
原文传递
导出
摘要 Background C-reactive protein (CRP) is a lowly expressed marker for inflammatory response. This study aimed to evaluate the prognostic value of baseline CRP levels in patients undergoing coronary revascularization in the context of modern medical treatment. Methods This was a retrospective study in a single center. Four hundred and fourteen patients were enrolled, who underwent coronary revascularization and received adequate medication for secondary prevention of coronary heart disease. The study compared the follow-up clinical outcomes between high level CRP group (CRP 〉5 mg/L) and low level one. The median follow-up time was 551 days. Results Compared with low CRP group, the relative risk (RR) of the major adverse cardiovascular and cerebral events (MACCE) in high CRP group was 5.131 (95% CI: 1.864-14.123, P=0.002). There were no significant differences in death myocardial infarction and stroke during the follow-up between two groups, but a higher risk of re-revascularization was found in high CRP group (RR 6.008, 95% CI: 1.667-21.665, P=0.006). Cox regression analysis showed that only CRP level could contribute to MACCE during the follow-up. MACCE-free rate was much lower in high CRP group (Kaplan-Meier log-rank P 〈0.001). Conclusion In the context of modern medical treatment, the baseline level of CRP is an independent predictor for long-term prognosis in patients with coronary revascularization. Background C-reactive protein (CRP) is a lowly expressed marker for inflammatory response. This study aimed to evaluate the prognostic value of baseline CRP levels in patients undergoing coronary revascularization in the context of modern medical treatment. Methods This was a retrospective study in a single center. Four hundred and fourteen patients were enrolled, who underwent coronary revascularization and received adequate medication for secondary prevention of coronary heart disease. The study compared the follow-up clinical outcomes between high level CRP group (CRP 〉5 mg/L) and low level one. The median follow-up time was 551 days. Results Compared with low CRP group, the relative risk (RR) of the major adverse cardiovascular and cerebral events (MACCE) in high CRP group was 5.131 (95% CI: 1.864-14.123, P=0.002). There were no significant differences in death myocardial infarction and stroke during the follow-up between two groups, but a higher risk of re-revascularization was found in high CRP group (RR 6.008, 95% CI: 1.667-21.665, P=0.006). Cox regression analysis showed that only CRP level could contribute to MACCE during the follow-up. MACCE-free rate was much lower in high CRP group (Kaplan-Meier log-rank P 〈0.001). Conclusion In the context of modern medical treatment, the baseline level of CRP is an independent predictor for long-term prognosis in patients with coronary revascularization.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2010年第13期1628-1632,共5页 中华医学杂志(英文版)
关键词 C reactive protein coronary heart disease REVASCULARIZATION PROGNOSIS C reactive protein coronary heart disease revascularization prognosis
  • 相关文献

参考文献16

  • 1Tsimikas S,Willerson JT,Ridker PM.C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.J Am Coll Cardiol 2006; 47(8 Suppl):C19-C31.
  • 2Currie CJ,Poole CD,Conway P.Evaluation of the association between the first observation and the longitudinal change in C-reactive protein,and all-cause mortality.Heart 2008; 94:457-462.
  • 3Saleh N,Tornvall P.Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis.Atherosclerosis 2007; 195:374-378.
  • 4Lindahl B,Toss H,Siegbahn A,Venge P,Wallentin L.Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease.FRISC Study Group.Fragmin during Instability in Coronary Artery Disease.N Engl J Med 2000; 343:1139-1147.
  • 5Ridker PM,Buring JE,Cook NR,Rifai N.C-reactive protein,the metabolic syndrome,and risk of incident cardiovascular events:an 8-year follow-up of 14 719 initially healthy American women.Circulation 2003; 107:391-397.
  • 6Ridker PM,Cushman M,Stampfer MJ,Tracy RP,Hennekens CH.Inflammation,aspirin,and the risk of cardiovascular disease in apparently healthy men.N Engl J Med 1997; 336:973-979.
  • 7Ridker PM,Rifai N,Pfeffer MA,Sacks FM,Moye LA,Goldman S,et al.Inflammation,pravastatin,and the risk of coronary events after myocardial infarction in patients with average cholesterol levels:Cholesterol and Recurrent Events (CARE) Investigators.Circulation 1998; 98:839-844.
  • 8Bickel C,Rupprecht HJ,Blankenberg S,Espiniola-Klein C,Schlitt A,Rippin G,et al.Relation of markers of inflammation (C-reactive protein,fibrinogen,von Willebrand factor,and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease.Am J Cardiol 2002; 89:901-908.
  • 9Gurbel PA,Bliden KP,Tantry US.Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting:results from the CLEAR PLATELETS lb study.J Am Coll Cardiol 2006; 48:2186-2191.
  • 10Macaya C,Garcia-Garcia HM,Colombo A,Morice MC,Legrand V,Kuck KH,et al.One-year results of coronary revascularization in diabetic patients with multivessel coronary artery disease.Sirolimus stent vs.coronary artery bypass surgery and bare metal stent:insights from ARTS II and ARTS I.Eurolntervention 2006; 2:69-76.

同被引文献11

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部